For example, in an autochthonous BRAFV600EPTEN-/- melanoma model, a TβRI kinase inhibitor augmented the effects of anti-CTLA-4 treatment but failed to augment the effects of anti-PD-1/PD-L1 blockade. This evidence concerns the gene CTLA4 and melanoma.